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Background: Pulmonary hypertension is common in patients with aortic stenosis. The immediate effect of transcatheter aortic valve replacement 
(TAVR) on pulmonary arterial (PA) pressures is unknown.
Methods: We performed a single-center cohort study of patients undergoing TAVR (Edwards Sapien). We compared within-patient differences in 
invasively measured PA pressures immediately before and after TAVR and echocardiographic estimated PA systolic pressure 30 days after TAVR.
Results: 71 patients (87.7±5.2 years age, 41% male) underwent TAVR; 53% of patients had depressed LV ejection fraction <55%, 25% had PA 
mean pressure >25 mm Hg, 39% had pulmonary vascular resistance >3 Wood Units, and 38% had wedge pressure >15 mm Hg at baseline. TAVR 
resulted in increased cardiac index and decreased systemic vascular resistance (Table). However, PA pressures increased significantly immediately 
after TAVR; 52% of patients had an increase in PA systolic pressure by >5mm Hg. Increased PA systolic pressure was sustained as evaluated by 
30-day echocardiography (Table, p<0.001). There were no deaths at 30 days and no difference in hospital length of stay between patients with or 
without baseline PA mean pressure >25 mm Hg.
Conclusion: Over half of patients undergoing TAVR have acute and 30-day increased PA pressures despite improved afterload and cardiac output. 
Longer-term studies are needed to evaluate the impact of TAVR on pulmonary hypertension and related outcomes.
Hemodynamic Changes after TAVR
Mean difference after TAVR P (paired)
Mean aortic gradient (mm Hg) -36.1±16.9 <0.001
Cardiac index (L/min/m2) 0.3 ± 0.70 0.003
Systemic vascular resistance (dynes/s/cm5) - 417 ± 807 <0.001
PA systolic pressure (mm Hg) 7.9 ± 10.8 <0.001
PA mean pressure (mm Hg) 5.5 ± 8.4 <0.001
PA diastolic pressure (mm Hg) 4.7 ± 8.0 <0.001
Wedge pressure (mm Hg) 2.6 ± 6.7 0.002
Pulmonary vascular resistance (Woods Units) 0.4 ± 2.6 0.20
30 day PA systolic pressure (by echo, mm Hg) 9.4 ±12.2 <0.001
